BAKER BROS. ADVISORS LP 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-22 4:15 pm Purchase | 2024-08-21 | 13D | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 6,001,262 9.300% | 3,556 (+0.06%) | Filing |
| 2024-04-01 08:57 am Purchase | 2024-03-28 | 13D | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 5,997,706 9.800% | 1,778 (+0.03%) | Filing |
| 2024-01-10 4:52 pm Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 5,995,928 10.800% | 3,116,103 (+108.20%) | Filing |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 2,879,825 5.200% | 2,879,825 (New Position) | Filing |